Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

Volume: 367, Issue: 7, Pages: 616 - 624
Published: Aug 15, 2012
Abstract
The primary outcome, clinical response at 8 weeks, occurred in 32%, 48%, 61%, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.39), 3 mg (P = 0.55), 10 mg (P = 0.10), and 15 mg (P 1) at 8 weeks occurred in 13%, 33%, 48%, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.76), 3 mg (P = 0.01), 10 mg (P<0.001), and 15 mg (P<0.001), respectively, as compared with 10% of patients receiving placebo. There was a...
Paper Details
Title
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Published Date
Aug 15, 2012
Volume
367
Issue
7
Pages
616 - 624
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.